Mesenchymal stem cell therapy - Translational Biosciences

Drug Profile

Mesenchymal stem cell therapy - Translational Biosciences

Latest Information Update: 07 Sep 2016

Price : $50

At a glance

  • Originator Translational Biosciences
  • Class Antineoplastics; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Multiple sclerosis; Osteoarthritis

Most Recent Events

  • 17 Mar 2016 Mesenchymal stem cell therapy is still in phase I/II trials for Osteoarthritis and Multiple sclerosis in Panama
  • 09 Jan 2014 Phase-I/II clinical trials in Multiple sclerosis in Panama (IV)
  • 31 Dec 2013 Phase-I/II clinical trials in Osteoarthritis in Panama (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top